• Explore /
  • Poster
  • / Atezolizumab (atezo) with or without Bacille Calmette-Guérin (BCG) in patients (pts) with high-risk nonmuscle-invasive bladder cancer (NMIBC): Results from a phase Ib/II study.

Atezolizumab (atezo) with or without Bacille Calmette-Guérin (BCG) in patients (pts) with high-risk nonmuscle-invasive bladder cancer (NMIBC): Results from a phase Ib/II study.

Abstract Video & Slides Poster

Authors

Noah Hahn

Noah M. Hahn

Johns Hopkins Greenberg Bladder Center Institute, Johns Hopkins School of Medicine, Baltimore, MD

Noah M. Hahn , Gary D. Steinberg , Kelly Lynn Stratton , Ryan P. Kopp , Alexander Sankin , Eila C. Skinner , Kamal S. Pohar , Benjamin Adam Gartrell , Song Pham , Deepali Rishipathak , Sanjeev Mariathasan , Nicole N. Davarpanah , Corey Carter , Brant Allen Inman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02792192

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 493)

DOI

10.1200/JCO.2022.40.6_suppl.493

Abstract #

493

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Daniel Castellano

First Author: Neal D. Shore

First Author: Ashish M. Kamat

Poster

2022 ASCO Genitourinary Cancers Symposium

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma.

First Author: Shruthi Naik